(BUSINESS WIRE)--Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI). This achievement represents rapid progress for the collaboration, which was launched in September 2010 to develop G protein coupled receptor (GPCR)–targeted therapeutic compounds utilizing Anchor’s proprietary pepducin technology.
